Alpha 2.0
Login Register
» Authors » Irene van der Horst-Bruinsma

Irene van der Horst-Bruinsma

Explore the profile of Irene van der Horst-Bruinsma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 39
Citations 1188
Followers 0
Related Specialties
Rheumatology
Genetics
Rehabilitation Medicine
Top 10 Co-Authors
Mikkel Ostergaard
Ziga Rotar
Bjorn Gudbjornsson
Merete Lund Hetland
Brigitte Michelsen
Adrian Ciurea
Anne Gitte Loft
Florenzo Iannone
Lykke Midtboll Ornbjerg
Catalin Codreanu
Published In
J Rheumatol
Ann Rheum Dis
Rheumatology (Oxford)
RMD Open
Semin Arthritis Rheum
Affiliations
Soon will be listed here.
Recent Articles
1.
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
Polysopoulos C, Georgiadis S, Ornbjerg L, Scherer A, Di Giuseppe D, Hetland M, et al.
BMC Med Res Methodol . 2025 Feb; 25(1):55. PMID: 40021967
Background: Observational data on composite scores often comes with missing component information. When a complete-case (CC) analysis of composite scores is unbiased, preferable approaches of dealing with missing component information...
2.
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network
Pons M, Georgiadis S, Hetland M, Faizy Ahmadzay Z, Rasmussen S, Christiansen S, et al.
J Rheumatol . 2025 Feb; PMID: 39892891
Objective: In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by...
3.
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries
Ciurea A, Kissling S, Gotschi A, Ornbjerg L, Rasmussen S, Tamasi B, et al.
Arthritis Res Ther . 2025 Jan; 27(1):18. PMID: 39891200
Background: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated...
4.
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
Pons M, Georgiadis S, Ostergaard M, Faizy Ahmadzay Z, Glintborg B, Heberg J, et al.
Joint Bone Spine . 2024 Nov; 92(3):105824. PMID: 39608666
Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according...
5.
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study
Christiansen S, Rasmussen S, Ostergaard M, Pons M, Michelsen B, Pavelka K, et al.
RMD Open . 2024 Jul; 10(3. PMID: 39053949
Objectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods: Prospectively collected data on secukinumab-treated...
6.
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Brown M, Rudwaleit M, van Gaalen F, Haroon N, Gensler L, Fleurinck C, et al.
Ann Rheum Dis . 2024 Jul; 83(12):1722-1730. PMID: 38977276
Objectives: Acute anterior uveitis ('uveitis') is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis...
7.
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
Georgiadis S, Ornbjerg L, Michelsen B, Kvien T, Di Giuseppe D, Wallman J, et al.
J Rheumatol . 2024 Apr; 51(7):673-677. PMID: 38621792
Objective: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although...
8.
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
Christiansen S, Rasmussen S, Pons M, Michelsen B, Glintborg B, Gudbjornsson B, et al.
Semin Arthritis Rheum . 2024 Feb; 65:152388. PMID: 38301349
Objectives: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes...
9.
Generating a list of potentially important contextual factors covering randomized trials, cohorts, and measurement property studies: An OMERACT initiative
Weinbrecht-Mischkewitz M, Kamal M, Asim F, Guillemin F, Goel N, Voshaar M, et al.
Semin Arthritis Rheum . 2024 Jan; 65:152370. PMID: 38290371
Objectives: To generate candidates for contextual factors (CFs) for each CF type (i.e., Effect Modifying Contextual Factors (EM-CFs), Outcome Influencing Contextual Factors (OI-CFs), and Measurement Affecting Contextual Factors (MA-CFs)) considered...
10.
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial
Lend K, van Vollenhoven R, Lampa J, Hetland M, Haavardsholm E, Nordstrom D, et al.
Lancet Rheumatol . 2024 Jan; 4(10):e688-e698. PMID: 38265967
Background: Rheumatoid arthritis is a chronic inflammatory disease with a well-recognised female preponderance. In this post-hoc analysis of the NORD-STAR trial, we aimed to examine sex differences in remission rates...